Ribo and Boehringer Advance siRNA MASH Program
SUZHOU, China, May 6, 2026 Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced the achievement of...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SUZHOU, China, May 6, 2026 Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced the achievement of...
IRVINE, Calif., May 6, 2026 Helio Genomics announced publication of landmark clinical data demonstrating that its HelioLiverâ„¢ multi-analyte blood...
